Pacira BioSciences (PCRX) Total Current Liabilities (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Total Current Liabilities of $108.8 million for Q1 2026, down 65.44% year-over-year from $314.7 million in Q1 2025, and down 9.79% quarter-over-quarter from $120.6 million in Q4 2025.
Pacira BioSciences (PCRX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Pacira BioSciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $108.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 65.44% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $108.8 million (down 65.44% YoY), while the FY2025 annual figure was $120.6 million, down 61.09% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $108.8 million, down from $120.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $314.7 million in Q1 2025, with the low at $92.7 million in Q2 2024.
- The 5-year median for Total Current Liabilities is $120.6 million (2025), against an average of $169.6 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities slumped 71.64% in 2022, then jumped 237.86% in 2025.
- Pacira BioSciences' Total Current Liabilities stood at $147.8 million in 2022, then plunged by 34.1% to $97.4 million in 2023, then jumped by 218.25% to $309.9 million in 2024, then slumped by 61.09% to $120.6 million in 2025, then retreated by 9.79% to $108.8 million in 2026.
- Business Quant data shows PCRX's Total Current Liabilities at $108.8 million in Q1 2026, $120.6 million in Q4 2025, and $107.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Pacira BioSciences | 945.90 Mn | 694.87 Mn | 148.24 Mn | 122.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.01 Mn |
| Mar 31, 2026 | 108.79 Mn |
| Dec 31, 2025 | 120.59 Mn |
| Sep 30, 2025 | 107.08 Mn |
| Jun 30, 2025 | 313.16 Mn |
| Mar 31, 2025 | 314.73 Mn |
| Dec 31, 2024 | 309.92 Mn |
| Sep 30, 2024 | 306.40 Mn |
| Jun 30, 2024 | 92.69 Mn |
| Mar 31, 2024 | 93.44 Mn |
| Dec 31, 2023 | 97.38 Mn |
| Sep 30, 2023 | 93.66 Mn |
| Jun 30, 2023 | 108.91 Mn |
| Mar 31, 2023 | 98.70 Mn |
| Dec 31, 2022 | 147.77 Mn |
| Sep 30, 2022 | 131.53 Mn |
| Jun 30, 2022 | 133.18 Mn |
| Mar 31, 2022 | 305.07 Mn |
| Dec 31, 2021 | 521.12 Mn |
| Sep 30, 2021 | 225.79 Mn |